These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 34117117)

  • 21. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries.
    Hussain A; Rafeeq H; Asif HM; Shabbir S; Bilal M; Mulla SI; Franco M; Iqbal HMN
    Int Immunopharmacol; 2021 Oct; 99():108050. PubMed ID: 34426120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine.
    Nantel S; Bourdin B; Adams K; Carbonneau J; Rabezanahary H; Hamelin MÈ; McCormack D; Savard P; Longtin Y; Cheng MP; De Serres G; Corbeil J; Gilca V; Baz M; Boivin G; Quach C; Decaluwe H
    Front Immunol; 2022; 13():930252. PubMed ID: 36311736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.
    Gobbi F; Buonfrate D; Moro L; Rodari P; Piubelli C; Caldrer S; Riccetti S; Sinigaglia A; Barzon L
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
    Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
    Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mRNA vaccines for COVID-19: what, why and how.
    Park JW; Lagniton PNP; Liu Y; Xu RH
    Int J Biol Sci; 2021; 17(6):1446-1460. PubMed ID: 33907508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. To Vaccinate or not to Vaccinate; That is the Question! (New Insights into COVID-19 Vaccination).
    El-Nakeep S
    Curr Mol Med; 2022; 22(7):567-571. PubMed ID: 33982651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
    Moscara L; Venerito V; Martinelli A; Di Lorenzo A; Toro F; Violante F; Tafuri S; Stefanizzi P
    Vaccine; 2023 Aug; 41(38):5655-5661. PubMed ID: 37544827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 vaccines for cancer patients: a call to action.
    Corti C; Crimini E; Tarantino P; Pravettoni G; Eggermont AMM; Delaloge S; Curigliano G
    Eur J Cancer; 2021 May; 148():316-327. PubMed ID: 33770576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases.
    Poparn H; Srichumpuang C; Sosothikul D; Jantarabenjakul W; Lauhasurayotin S; Techavichit P; Chiangthong K; Poovorawan Y
    Asian Pac J Cancer Prev; 2022 Jun; 23(6):2049-2055. PubMed ID: 35763647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
    Apostolidis SA; Kakara M; Painter MM; Goel RR; Mathew D; Lenzi K; Rezk A; Patterson KR; Espinoza DA; Kadri JC; Markowitz DM; E Markowitz C; Mexhitaj I; Jacobs D; Babb A; Betts MR; Prak ETL; Weiskopf D; Grifoni A; Lundgreen KA; Gouma S; Sette A; Bates P; Hensley SE; Greenplate AR; Wherry EJ; Li R; Bar-Or A
    Nat Med; 2021 Nov; 27(11):1990-2001. PubMed ID: 34522051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19.
    Chang A; Yu J
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 mRNA vaccines.
    Huang Q; Zeng J; Yan J
    J Genet Genomics; 2021 Feb; 48(2):107-114. PubMed ID: 34006471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Vaccination contre le SARS-CoV-2, le Graal ?].
    Binh Luong Nguyen L; Lachâtre M; Launay O
    Rev Prat; 2022 May; 72(5):517-522. PubMed ID: 35899638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.
    Budziar W; Gembara K; Harhala M; Szymczak A; Jędruchniewicz N; Baniecki K; Pikies A; Nahorecki A; Hoffmann A; Kardaś A; Szewczyk-Dąbrowska A; Klimek T; Kaźmierczak Z; Witkiewicz W; Barczyk K; Dąbrowska K
    PLoS One; 2022; 17(2):e0253638. PubMed ID: 35113873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines.
    Matsumura T; Takano T; Takahashi Y
    Int Immunol; 2023 May; 35(5):213-220. PubMed ID: 36566501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.